Enki

Enki was a biotechnology company focused on the development of a new class of topical therapies for the treatment of skin cancer and inflammatory skin diseases. Spun out of research from Yale University, the company specialized in creating localized treatments designed to maximize therapeutic efficacy while minimizing systemic side effects. Its lead research programs targeted cutaneous T-cell lymphoma (CTCL) and other dermatological conditions such as psoriasis and atopic dermatitis. The company's approach utilized small molecule modulators of immune pathways, including JAK inhibitors and TLR agonists, formulated for topical delivery.